2. UroToday Home
  3. Video Lectures

ASCO GU 2021 Prostate Cancer Videos

HHV-8 Positive Clinically Advanced mCRPC & Genomic Landscape of CDK12 Mutated mCRPC - Petros Grivas
May 21, 2021
Details
Advancing Knowledge About The Treatment of Advanced Prostate Cancer, Highlights from GU ASCO 2021 - Praful Ravi
May 5, 2021
Details
Associations of circulating cell-free DNA (cfDNA) and clinical outcomes in metastatic castrate-resistant prostate cancer (mCRPC): A Discussion on the Data - Daniel Shevrin
April 21, 2021
Details
Cabazitaxel is Active in Men with mCRPC with DDR Alterations - Karim Fizazi and Mihaela Aldea
April 11, 2021
Details
Talazoparib Monotherapy in Men with DNA Damage Response Alterations (TALAPRO-1) - Celestia Higano
April 1, 2021
Details
Baseline Pathogenic Mutations in Metastatic Castration-Resistant Prostate Cancer Patients Being Treated with High-Dose Testosterone - Oliver Sartor
March 28, 2021
Details
Landscape of Circulating Tumor DNA Abnormalities in Advanced Prostate Cancer: Distinctions Between African-American and Caucasians - Pedro Barata
March 24, 2021
Details
177 Lu-PSMA-617 Offers a Promising Treatment for Men with Progressing mCRPC. - Declan Murphy & Michael Hofman
March 22, 2021
Details
The Modifiers That Impact Response to the PARP Inhibitor Rucaparib from TRITON2 - Wassim Abida
March 19, 2021
Details
PROSPER Trial Demonstrates the Relationship Between the Degree of PSA Decline and Survival Outcomes - Cora Sternberg
March 12, 2021
Details
Genomics Guide Treatment Decisions in Post Prostatectomy Patients - Ashley Ross
March 11, 2021
Details
Radium-223 plus Enzalutamide vs Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer - Benjamin Maughan
March 9, 2021
Details
Evaluating Circulating Tumor Cells in Patients on the CARD Trial - Eleni Efstathiou
March 6, 2021
Details
Practice Patterns of Metastatic Castration-Sensitive Prostate Cancer in the Veterans Healthcare Administration - Stephen Freedland & Scott Tagawa
March 5, 2021
Details
Androgen Annihilation with Abiraterone and Apalutamide in Chemo-Naïve mCRPC - Final Results from ACIS- Dana Rathkopf & Fred Saad
March 1, 2021
Details
Biological Signatures of Patients with Long-Term Responses to Apalutamide and Placebo in Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)- Felix Feng
February 26, 2021
Details
The Combination of Pembrolizumab and Radium-223 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Atish Choudhury
February 26, 2021
Details
Biomarker Analysis from a Randomized Study of Olaparib With or Without Cediranib in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)- Rana Mckay
February 25, 2021
Details
Phase I RAMP Study Evaluating the Combination of Enzalutamide and Rucaparib in mCRPC - Arpit Rao
February 23, 2021
Details
PSMA-Directed CAR-T First-in-Human Trial in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Vivek Narayan
March 3, 2021
Details
Impact of Concomitant Prostate Cancer Therapy of Relugolix in Men with Advanced Prostate Cancer - Daniel J. George
February 22, 2021
Details
IPATential150 Trial in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Cora Sternberg
February 18, 2021
Details
Nivolumab Plus Docetaxel for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer from CheckMate 9KD Arm B, - Karim Fizazi
February 15, 2021
Details
Sequential Radium-223 Treatment of mCRPC That Progressed After First-Line Novel Antihormonal Therapy, A Real-World Clinical Outcomes Study - Oliver Sartor
February 14, 2021
Details
Comparing Lutetium-PSMA Vs. Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC) - Thera-P Trial - Michael Hofman
February 14, 2021
Details